Tyrosine kinase inhibitors in first-line treatment of advanced NSCLC with epidermal growth factor receptor mutations: Real-world data from Vietnam
Oncology Research · 2025
DOI: 10.32604/or.2025.061905 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Khanh Toan Nguyen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology 2, Nghe An Oncology Hospital, Vinh City, 43000, Vietnam. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Protein Kinase Inhibitors, Lung Neoplasms, Mutation. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology 2, Nghe An Oncology Hospital, Vinh City, 43000, Vietnam.
Zitieren
APA
Nguyen, K. T., Pham, T. H., Ngo, V. L., Bui, V. T., Nguyen, V. N., Nguyen, T. P. T., Nguyen, T. K. H., & Nguyen, T. T. V. (2025). Tyrosine kinase inhibitors in first-line treatment of advanced NSCLC with epidermal growth factor receptor mutations: Real-world data from Vietnam. Oncology Research. https://doi.org/10.32604/or.2025.061905
Vancouver
Nguyen KT, Pham TH, Ngo VL, Bui VT, Nguyen VN, Nguyen TPT, et al. Tyrosine kinase inhibitors in first-line treatment of advanced NSCLC with epidermal growth factor receptor mutations: Real-world data from Vietnam. Oncology Research. 2025. doi:10.32604/or.2025.061905
BibTeX
@article{Nguyen2025,
author = {Nguyen, Khanh Toan and Pham, Thi Huong and Ngo, VAN Lam and Bui, VAN Tuan and Nguyen, VAN Nhat and Nguyen, Thi Phuong Thao and Nguyen, Thi Khanh Ha and Nguyen, Thi Thuy VAN},
title = {Tyrosine kinase inhibitors in first-line treatment of advanced NSCLC with epidermal growth factor receptor mutations: Real-world data from Vietnam},
journal = {Oncology Research},
year = {2025},
doi = {10.32604/or.2025.061905}
}
EUVIMED